Altmann, DM; Boyton, RJ; Beale, R; (2021) Immunity to SARS-CoV-2 variants of concern. Science , 371 (6534) pp. 1103-1104. 10.1126/science.abg7404.

Preview

Text Beale_Immunity to SARS-CoV-2 variants of concern Altmann Boyton Beale Accepted version.pdf - Accepted Version Download (93kB) | Preview

Abstract

Vaccine candidates based on spike, the glycoprotein that is essential for host cell entry by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being designed within days of its reported sequence in January 2020. All the vaccines aim to prevent disease primarily (but not exclusively) by eliciting neutralizing antibodies that block spike and therefore prevent the ability of SARS-CoV-2 to infect cells. The 95% efficacy of the BNT162b2 messenger RNA (mRNA) vaccine (from Pfizer/BioNTech) heralded a series of results showing that eliciting neutralizing antibodies to spike strongly correlated with protection from disease in clinical trials of various vaccines. Currently, there is concern about reduced vaccine-induced immune protection to emerging variants that have mutations in the spike protein. On page 1152 of this issue, Muik et al. (1) found reduced induction of neutralizing antibodies from BNT62b2. However, there is likely sufficient efficacy remaining to confer protection from symptomatic disease.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item